Heiner Ebel

USPTO Granted Patents = 18 (Patent Applications = 3)

CIPO Patents = 4

EPO Patents = 19 (Patent Applications = 18)

Average Co-Inventor Count = 5.9

ph-index = 7

Forward Citations = 83(Granted Patents)

Location History:

Biberach, DE (2010 - 2014)
Mettenberg, DE (2015)
Biderach an der Riss, DE (2015)
Biberach an der Riss, DE (2014 - 2023)

Company Filing History:

13 out of 1,536

Boehringer Ingelheim International Gmbh

patents

5 out of 36

Centrexion Therapeutics Corporation

patents

Years Active: 2010-2025

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12209094 - CCR2 receptor antagonists and uses thereof (2025-01-28),

2. 11731981 - CCR2 receptor antagonists and uses thereof (2023-08-22),

3. 11046706 - CCR2 receptor antagonists and uses thereof (2021-06-29),

4. 10196402 - CCR2 receptor antagonists and uses thereof (2019-02-05),

5. 9670222 - CCR2 receptor antagonists and uses thereof (2017-06-06),

6. 9108958 - Selective CCR2 antagonists (2015-08-18),

7. 9067951 - Process and intermediates for the production of CCR2 antagonists (2015-06-30),

8. 9029360 - Pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists (2015-05-12),

9. 9018212 - Pyridazine carboxamides as CCR2 receptor antagonists (2015-04-28),

10. 8962656 - CCR2 antagonists (2015-02-24),

11. 8946218 - CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments (2015-02-03),

12. 8877745 - CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments (2014-11-04),

13. 8841313 - CCR2 antagonists and uses thereof (2014-09-23),

14. 8835440 - Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD (2014-09-16),

15. 8765949 - CCR2 receptor antagonists and uses thereof (2014-07-01),

Title: The Innovative Journey of Inventor Heiner Ebel

Introduction:

Heiner Ebel, a talented inventor based in Biberach an der Riss, DE, has made significant contributions to the field of medicine through his innovative patents. With a total of 17 patents to his name, Ebel has focused on developing novel solutions for treating various conditions and diseases, particularly in the realm of pulmonary health.

Latest Patents:

One of Ebel's latest patents is for CCR2 receptor antagonists and their uses, which are designed to provide medicaments for treating conditions such as asthma and COPD. These novel antagonists target the CC chemokine receptor 2, offering new possibilities for combating pulmonary diseases and improving patient outcomes.

Career Highlights:

Throughout his career, Heiner Ebel has been associated with renowned companies in the pharmaceutical and biotechnology sectors. Some of the notable companies he has worked for include Boehringer Ingelheim International GmbH and Centrexion Therapeutics Corporation. His expertise and dedication have played a vital role in advancing medical research and innovation within these organizations.

Collaborations:

In his professional journey, Heiner Ebel has collaborated with esteemed colleagues such as Sara Frattini and Riccardo Giovannini. Together, they have synergized their skills and knowledge to drive forward groundbreaking projects and bring about transformative developments in the medical field.

Conclusion:

Inventor Heiner Ebel's inventive spirit and commitment to improving healthcare have resulted in a remarkable portfolio of patents that have the potential to make a significant impact on the lives of individuals battling pulmonary diseases. His collaborations with industry experts and relentless pursuit of innovation underscore his outstanding contributions to the realm of medical research.

This text is generated by artificial intelligence and may not be accurate.